According to the latest report by IMARC Group, titled “Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," the global glioblastoma multiforme treatment market size reached US$ 2.0 Billion in 2022. Glioblastoma multiforme (GBM) refers to an aggressive and malignant brain tumor that arises from the supportive tissues of the brain. Its symptoms include nausea, headache, vomiting, seizures, weakness, difficulty speaking, cognitive decline, personality changes, and motor deficits. It is diagnosed through neurological examinations, cognitive assessments, biopsy, and various imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans. GBM treatment involves medications, surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. These treatments prevent tumor growth, kill cancer cells, slow disease progression, stimulate the immune system, and alleviate various symptoms. They also aid in improving clinical outcomes, increasing survival rates, regaining lost motor functions, and enhancing patients’ quality of life.
Glioblastoma Multiforme Treatment Market Trends:
The rising incidence of GBM due to inherited genetic conditions, radiation exposure, and environmental factors is one of the primary factors creating a positive outlook for the market. GBM treatments are widely used to slow down the progression of the disease, prevent tumor growth, kill cancer cells, increase patients’ survival rate, and manage various symptoms, such as headaches, seizures, and neurological deficits. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of GBM to improve clinical outcomes, prevent future complications, reduce healthcare expenditure, and enhance patients’ quality of life is providing an impetus to the market growth. Additionally, the recent development of tumor treating fields (TTF) therapy, which is a non-invasive treatment that utilizes electrical fields to disrupt cell division and slow down cancer progression, is positively influencing the market growth. Apart from this, the integration of artificial intelligence (AI)-based algorithms to improve the accuracy of diagnosis, identify the best treatment plan, predict patient outcomes, and aid clinicians in making informed decisions is providing a thrust to the market growth. Moreover, the implementation of various government initiatives to improve healthcare infrastructure and provide access to high-quality treatment options is facilitating the market growth. Other factors, including rising healthcare expenditure, increasing investment in the research and development (R&D) of advanced treatments, and the growing numbers of drug approval, are anticipated to drive the market growth. On account of the aforementioned factors, the market value is expected to reach US$ 3.1 Billion by 2028, exhibiting a CAGR of 7.6% during 2023-2028.
- On the basis of the drug type, the market has been divided into temozolomide, bevacizumab, carmustine, radiosensitizer, and others.
- Based on the route of administration, the market has been bifurcated into oral and parenteral.
- On the basis of the type of molecule, the market has been classified into small molecule and biologics.
- Based on the distribution channel, the market has been divided into hospitals, pharmacies, and others.
- On a regional basis, the market has been categorized into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
- The competitive landscape of the industry has also been examined, with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals.
|Base Year of the Analysis
||Drug Type, Route of Administration, Type of Molecule, Distribution Channel, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800